BackARS Pharmaceuticals Overview

ARS Pharmaceuticals EBIT

EBIT (Earnings Before Interest and Taxes) analysis for SPRY.

Quarterly EBIT

-$60.15M
↓ 61.78% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$197.64M
↓ 630.96% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin